Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple myeloma after first or subsequent relapse.
- Darzalex Faspro is co-formulated with recombinant human hyaluronidase PH20, Halozyme Therapeutics Inc's (NASDAQ:HALO) Enhanze drug delivery technology.
- The Company for drug comes in combination with pomalidomide and dexamethasone (Pd) to treat adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor.
- The approval marks Janssen's sixth indication for Darzalex Faspro in the treatment of multiple myeloma.
- The approval is supported by data from the Phase 3 APOLLO study, which met its primary endpoint of improved progression-free survival.
- Price Action: HALO shares are up 1.43% at $46.15 during the premarket session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!